Based on clinical practice, it could be predicted that, as mentioned earlier, the group of HR+/HER2− patients in both local, advanced, or metastatic cancer would be the most suitable for receiving the combination therapies detailed in Table 4. The gene discussed is HR; the disease is metastatic malignant neoplasm.